Alpha-fetoprotein-producing primary lung carcinoma: A case report

Aalpha-fetoprotein (AFP) is a type of protein formed in the fetal liver and yolk sac and is detected in the fetal serum. In regard to the pathological significance of this protein in adults, serum AFP is often elevated in patients with liver cancer or gonadal germ cell tumors, such as yolk sac tumor. Because the serum AFP level decreases in response to effective treatment, measurement of the serum AFP level is carried out during follow-up of patients after treatment or for the detection of tumor recurrence. AFP-producing ovarian cancer and gastric cancer have also been reported, whereas AFP-producing liver cancer is rare. Because AFP-producing lung cancer has scarcely been reported, the clinical features of this type of lung cancer are still unclear. In this context, we report a case of this type of cancer that we encountered recently.

A 69-year-old man consulted a nearby internal medicine clinic with the chief complaint of epigastric pain. He was diagnosed as having gastroesophageal reflux and initiated on treatment. A chest x-ray performed at that time revealed a mass in the right lower lung field. The patient had a history of smoking (Brinkman index: 1800) and had been diagnosed earlier as having pulmonary emphysema. He had the past of the alcoholic hepatitis. His family history was not noteworthy. He was 160 cm tall and weighed 55 kg. Physical examination revealed no abnormalities. A chest x-ray revealed a mass measuring 65 mm in diameter in the right lower lung field (Figure 1). Chest CT revealed a lobulated mass measuring 65 mm in diameter involving S9 and S10 of the right lung, as well as an enlarged right hilar lymph node (Figure 2). Abdominal CT revealed no lesions in the liver, gallbladder, or pancreas. FDG-PET revealed uptake in the mass (SUV: 8.1) in the right lung and in the swelling of #10 lymph node (SUV: 4.1). No abnormal FDG accumulation was noted in any other organ. Serum biochemical tests did not reveal any evidence of hepatic dysfunction or hepatitis B or C. Of the tumor markers, serum carbohydrate 12-5 (CA12-5), neuron-specific enolase (NSE), Sialyl Lewis X (SLX), β-human chorionic gonadotropin (βHCG), pro-gastrin releasing peptide (PRO-GRF), and cytokeratin 19 fragment (CYFRA) levels were within normal range, while the serum AFP was markedly elevated (4620 ng/ml), and serum carcinoembryonic antigen (CEA; 6.6 ng/ml) and carbohydrate antigen 19-9 (CA19-9; 46.6 ng/ml) were slightly elevated. Transbronchial lung biopsy led to the diagnosis of AFP-producing lung carcinoma. Surgical treatment was selected on the basis of the preoperative tumor stage (T2N0M0). Right lower lobectomy + mediastinal lymph node dissection excision was carried out by video assisted thoracic surgery. The resected tumor measured 6.5 cm in diameter and was a solid tumor (Figure 3). Histopathologically, the tumor was composed of tumor cells with relatively irregular nuclear sizes and cylindrical, partially eosinophilic and dimly bright cell bodies showing little polymorphism, leading to the diagnosis of moderately differentiated adenocarcinoma (p0, pm0, ly1, v0). Lymph node metastasis was noted in #7,#10 and #11i lymph nodes, which led to a revision of the tumor stage to T2bN2M0/stageIIIA. Immnohistochemical staining for AFP revealed positive staining of a number of tumor cells for AFP, leading to the diagnosis of AFP-producing lung adenocarcinoma (Figure 4,5). The cells also showed positive staining for cytokeratine (CK)18, CK19, and anti-hepatocyte antibody. Thus, although the histological and morphological features of the tumor differed from those of hepatocellular carcinoma, the chromatic responses of the tumor to immunostaining were close to those known for hepatocytes. Of the indicators of the tumor malignancy grade, tumor protein 53 was negative, and the MIB-1 index was slightly high (40%). The postoperative course was favorable, and the serum AFP level returned to normal range by about 2 weeks after the surgery. At present, the patient is receiving adjuvant chemotherapy (Tegafur-Uracil), and has not, until date, shown any signs of tumor recurrence.

AFP is one of the fetal proteins with a molecular weight that is intermediate between that of albumin and α1-globulin. It is produced by the fetal liver, yolk sac, and gastrointestinal cells. In relation to its pathological significance, serum AFP is useful as a tumor marker in patients with liver cancer. In adults showing elevated serum AFP levels, the malignant diseases requiring differential diagnosis include liver cancer, germ cell tumors (e.g., yolk sac tumor), and metastatic lung cancer, and the benign diseases requiring differential diagnosis include acute or chronic hepatitis, liver cirrhosis, and congenital biliary atresia [1‐3]. It has been reported that AFP-producing tumors account for about 2%-8% of all cases of gastric cancer, and that the percentage is higher among cases of advanced gastric cancer [4, 5]. Only a small number of reports have been published of cases with AFP-producing lung cancer; therefore, the pathophysiology and clinical characteristics of AFP-producing lung cancer have not yet been adequately clarified.

AFP-producing lung cancer was first reported by Corlin et al. [6] and has since been reported to account for about 2% of all lung cancers [7]. Histologically, adenocarcinoma (often poorly differentiated adenocarcinoma) accounts for the most of AFP-producing lung cancers. Furthermore, large-cell carcinoma accounts for 25% of all AFP-producing lung cancers. Thus, adenocarcinoma and large-cell carcinoma account for nearly all cases of AFP-producing lung cancer [8], although rare cases of AFP-producing squamous cell carcinoma [9] and AFP-producing carcinoid [10] have also been reported. As stated above, AFP-producing gastric cancer shows a high propensity for metastasizing to the liver and lymph nodes, and its prognosis is reported to be poorer as compared with that of non-AFP-producing gastric cancer. In relation to AFP-producing lung cancer, it must be kept in mind during the follow-up of these patients that the percentage of cases with poorly differentiated adenocarcinoma and the frequency of a high MIB-1 index are significantly higher in these cases than in those with non-AFP-producing liver cancer [11] during the follow-up of patients.

In regard to tumor markers, cases of AFP-producing liver cancer presenting with elevated serum CEA or HCG levels have been reported [12]. In the present case also, slight elevation of the serum CEA and CA19-9 levels was noted in addition to elevation of the serum AFP. The serum levels of these tumor markers returned to normal soon after tumor resection, and their pathological significance remained unknown.

The concept "hepatoid carcinoma" has been proposed in connection with this disease [13, 14]. This concept is used to indicate adenocarcinoma composed of a mixture of hepatoid components (cancer assuming the form of a hepatocellular carcinoma) and papillary components. Cases of hepatoid carcinoma affecting the pancreas, kidney, duodenum, gallbladder, etc. have been reported. Immunohistochemically, AFP is found in both the hepatoid component and the papillary component of hepatoid carcinomas. If the hepatoid component is dominant, the term "hepatoid-adenocarcinoma" is used. When the tumor keratin expression profile was analyzed in the present case, a very small percentage of the cells were found to be positive for CK7, whereas CK20 and TIF-1 were negative, the profile thus differing slightly from the profile known for typical lung cancer. However, the tumor in our patient also differed from hepatocellular carcinoma in terms of the histological and morphological features, which eventually led to the final diagnosis of AFP-producing lung adenocarcinoma. The number of cases with this type of tumor reported until date is rather small. Further accumulation of cases and analysis of data on the malignancy grade and long-term prognosis of AFP-producing lung adenocarcinoma would be desirable.

Informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.